타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Isatuximab |
Overview Company | Indapta Therapeutics, INC. |
Overview Modality | ANTIBODY |
Overview Target | Multiple Myeloma |
Overview Indication | NHL; Multiple Myeloma |
Overview Phase | PHASE_3 |
Overview Status | RECRUITING |
Overview Content status | Curated Core |
Overview Data Confidence | Editorial scope · Curated Core |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Positioning Key differentiator | unique mechanism of action of isatuximab, supporting preclinical data, and differentiation from other anti-CD38 antibodies |
Positioning Known limitation | resistance to these agents remains a major clinical challenge |
MoA Mechanism | targeted therapy, ADO concentrations in the BM remain well above the activation thresholds of P1 purinergic receptor |
MoA Biomarker | biomarkers and biologic profiling to enable optimal, integrated use of mAbs, ADCs, CAR T-cell therapies, and |
Toxicology Animal (cat.) | Unknown |
Toxicology CRS | Reported |
Clinical Safety signal | Reported |
Clinical Program phase | PHASE_3 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Isatuximab |
Overview Company | Indapta Therapeutics, INC. |
Overview Modality | ANTIBODY |
Overview Target | Multiple Myeloma |
Overview Indication | NHL; Multiple Myeloma |
Overview Phase | PHASE_3 |
Overview Status | RECRUITING |
Overview Content status | Curated Core |
Overview Data Confidence | Editorial scope · Curated Core |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Positioning Key differentiator | unique mechanism of action of isatuximab, supporting preclinical data, and differentiation from other anti-CD38 antibodies |
Positioning Known limitation | resistance to these agents remains a major clinical challenge |
MoA Mechanism | targeted therapy, ADO concentrations in the BM remain well above the activation thresholds of P1 purinergic receptor |
MoA Biomarker | biomarkers and biologic profiling to enable optimal, integrated use of mAbs, ADCs, CAR T-cell therapies, and |
Toxicology Animal (cat.) | Unknown |
Toxicology CRS | Reported |
Clinical Safety signal | Reported |
Clinical Program phase | PHASE_3 |
추천 비교
추천 비교